longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

C&Y Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 42.1901 million yuan, an increase of 67.45%

Zhitong
Apr 14, 2025 at 01:48 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, C&Y Pharmaceutical released its 2024 annual report, stating that the company's operating income was 847 million yuan, a year-on-year increase of 5.92%. The net profit attributable to shareholders of the listed company was 42.1901 million yuan, a year-on-year increase of 67.45%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.2287 million yuan. The basic earnings per share were 0.1746 yuan

According to the Zhitong Finance APP, C&Y Pharmaceutical (300254.SZ) released its annual report for 2024, reporting an operating income of 847 million yuan, a year-on-year increase of 5.92%. The net profit attributable to shareholders of the listed company was 42.1901 million yuan, a year-on-year increase of 67.45%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.2287 million yuan. The basic earnings per share were 0.1746 yuan

Login to unlock6characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

C&Y Pharmaceutical

C&Y Pharmaceutical

300254.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI